News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Penn Medicine and the Parker Institute for Cancer Immunotherapy (PICI) have renewed their collaboration to advance cancer immunotherapy research at Penn Medicine’s Abramson Cancer Center (ACC).
The list ranks “top academic institutions that play an enormous role in shaping the businesses that influence society”.
he Penn Center for Innovation is deeply saddened by the passing of Eric Corkhill, who served as Chairman and CEO of Neuralert Technologies.
During the 2022 fiscal year, there were 98 press mentions for PCI programs, startups and partners. Some of the most popular and widely circulated stories are included here.
The continued collaboration will support laboratory studies and clinical trials that leverage the science of cancer immunology.
This groundbreaking study, published in Cell, represents the largest antibiotic discovery effort to date, significantly accelerating the process of identification of candidate molecules.
Their “brewing” collaboration recently led to the development of a novel chip that uses light for vector-matrix multiplication.
A team of Penn researchers are exploring whether MRIs that measure the "temperature" of tumors could enhance treatment for glioblastoma, a deadly brain cancer.
The Fire Awards aim to celebrate the most promising businesses and individuals driving success and innovation locally in Greater Philadelphia.
The 2022 President’s Sustainability Prize winner Shinkei Systems was recognized in a recent article by Tech Crunch for its role in changing the seafood industry.